Estrogen increases the level of PD-1, PD-L1, and other checkpoint molecules in cancers, including ovarian cancer, which reduces the effectiveness of ICIs targeting the PD-1/PD-L1 pathway. This evidence concerns the gene PDCD1 and ovarian carcinoma.